Get the Daily Brief
Latest Biotech News
PTC Therapeutics’ Friedreich’s Ataxia Drug Faces FDA Setback
PTC Therapeutics’ vatiquinone, a candidate treatment for Friedreich’s ataxia, was rejected by the FDA due to insufficient evidence of efficacy. The agency requested a new, well-controlled study...
VantAI and Halda Therapeutics Launch $1B Proximity-Based Therapy Collaboration
VantAI, a generative AI company specialized in programmable protein interactions, and Halda Therapeutics have announced a strategic research collaboration valued over $1 billion to accelerate...
Advancements in Cancer Metabolism and Immune Evasion Mechanisms
Recent studies have unveiled novel insights into cancer biology including: the role of nerve injury-induced chronic inflammation in resistance to PD-1 immunotherapy; the metabolic interplay where...
AI and Digital Innovations Transform Bioprocessing and Drug Discovery
Multiple pioneering efforts demonstrate how artificial intelligence and digital technologies are revolutionizing bioprocessing and pharmaceutical R&D. Ginkgo Bioworks launched a partnership...
Innovations in Pediatric and Neonatal Care Technologies and Research
Pediatric and neonatal healthcare are advancing through novel diagnostic and therapeutic technologies. AI models now predict pulmonary hemorrhage risk in preterm infants, improving neonatal...
Biotech Sector M&A, IPO, and Financing Trends in 2025
The biotechnology industry in 2025 exhibits dynamic deal-making patterns with significant financing activities despite some challenges. Biopharma deal values have surged to record levels in the...
Graphene Stimulation Accelerates Brain Organoid Development
Researchers at the University of California San Diego have pioneered a graphene-mediated optical stimulation (GraMOS) technique that non-invasively accelerates the maturation of human brain...
Rocket Pharmaceuticals Resumes Gene Therapy Trials After FDA Hold
Rocket Pharmaceuticals has received FDA clearance to restart its Phase 2 trial of RP-A501 gene therapy for Danon disease following a clinical hold due to a patient death. The trial will proceed...
Viking Therapeutics’ Oral Obesity Drug Shows Efficacy but High Discontinuation
Viking Therapeutics reported positive Phase 2 data for its oral GLP-1/GIP dual agonist VK2735, achieving weight loss up to 12.2% at 13 weeks. Despite reaching efficacy endpoints, a substantial...
Celldex Therapeutics Discontinues Eosinophilic Esophagitis Program
Celldex Therapeutics announced it will cease development of barzolvolimab for eosinophilic esophagitis (EoE) despite meeting primary phase 2 endpoints related to mast cell depletion in the...
AI and Automation Revolutionize Biopharma Discovery and Manufacturing
Ginkgo Bioworks, Inductive Bio, and Tangible Scientific have partnered to create an integrated AI-driven lab-in-the-loop platform aimed at streamlining drug discovery workflows. This collaboration...
New Molecular Insights and Therapeutics in Cancer Research
Multiple groundbreaking studies have advanced understanding and treatment options across cancer types. Amgen presented AMG-410, a pan-KRAS inhibitor targeting diverse KRAS mutations prevalent in...
Advances in Imaging and Quantum Technologies
Researchers have introduced cutting-edge imaging and quantum control methodologies with broad impact. Nanjing University scientists developed a dual-frequency angular-multiplexed fringe projection...
FDA Actions and Biotech Regulatory Updates
The FDA has issued multiple notable regulatory decisions impacting the biotech sector. This includes lifting the clinical hold on Rocket Pharmaceuticals’ gene therapy trial for Danon disease with...
Cancer Biomarkers and Precision Diagnostics Progress
Recent studies have made significant strides in cancer diagnostics and prognostication. Natera’s Signatera circulating tumor DNA test successfully predicted improved disease-free and overall...
Rocket Pharmaceuticals Resumes Gene Therapy Trial After FDA Lift
Rocket Pharmaceuticals has received approval from the FDA to resume its Phase 2 gene therapy trial testing RP-A501 for Danon disease following a clinical hold. The hold was issued due to a patient...
Viking Therapeutics Oral Obesity Drug Spurs Investor Concern
Viking Therapeutics has reported mid-stage Phase 2 results for its oral weight loss drug VK-2735, demonstrating up to 12.2% mean weight reduction after 13 weeks. However, significant...
GraMOS Technique Accelerates Brain Organoid Maturation Using Graphene
Researchers at UC San Diego’s Sanford Stem Cell Institute have developed Graphene-Mediated Optical Stimulation (GraMOS), a novel non-genetic technique to accelerate the maturation of human brain...
Natera’s Signatera Test Predicts Survival Benefit with Tecentriq in Bladder Cancer
Natera announced statistically significant improvements in disease-free and overall survival for Signatera-positive muscle-invasive bladder cancer patients treated with Genentech's Tecentriq in...
VantAI and Halda Therapeutics Partner in $1 Billion Proximity-Based Therapy Collaboration
VantAI, a generative AI and protein interaction design company, entered a collaboration with Halda Therapeutics valued over $1 billion to develop novel selective proximity-based therapies across...